Breast CancerBreast CancerNCT07054957
Use of Handheld Fans in Management of Hot Flashes in Women With Breast Cancer Receiving Hormonetherapy
A study testing Handheld fan in people with Breast Cancer and Handheld Fan, run by Izmir Bakircay University at 1 site in Turkey (Türkiye).
Trial summary
Hot flushes are a common symptom in women with breast cancer receiving hormone therapy. It can lead to conditions that reduce quality of life such as sleep quality deterioration, sexual problems and discomfort in daily life. Effective management of the symptom improves the quality of life of patients. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer, Handheld Fan, Hot Flashes
- What is being tested?
- Handheld fan
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Nov 2023to 15 Oct 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Diagnosis of clinical breast cancer
- Experiencing hot flashes
Who cannot join
- Menopausal women
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Izmir Bakircay University
Izmir, Seyrek/Menemen, 35100
About this study
Hot flushes are a common symptom in women with breast cancer receiving hormone therapy. It can lead to conditions that reduce quality of life such as sleep quality deterioration, sexual problems and discomfort in daily life. Effective management of the symptom improves the quality of life of patients.
The aim of the study was to examine the effect of handheld fan use in the management of hot flashes in women with breast cancer receiving hormone therapy.
Read more
Hypotheses of the research:
H1: Handheld fan use has no effect in managing hot flashes in women with breast cancer receiving hormone therapy. H2: The use of handheld fan has an effect on the management of hot flashes in women with breast cancer receiving hormone therapy. This randomised controlled study was a pretest-posttest experimental design. The study sample consisted of 64 breast cancer patients (n = 32 for each of the intervention and control groups) receiving hormone therapy treatment in the medical oncology department of a university hospital. The intervention group used a hand-held fan when experiencing hot flush symptoms, while the control group did not receive any intervention. The pre-test and post-test Visual Analogue Scale (VAS) and hot flush belief scale scores and the results of the individual identifying information form were compared for both groups.
Read the detailed description
Study Design This study was conducted in a single-blind, single-center, randomized controlled design in breast cancer patients receiving hormone therapy in an outpatient chemotherapy unit.
This study was conducted in the outpatient chemotherapy unit of a training and research university hospital in Turkey Participants Power analysis was performed to determine the sample size of the study and the power of the test was calculated with G*Power 3.1 programme. Accordingly, with a margin of error of α=.05 and 80% power level, a total of 52 people, 26 people in each group, were found sufficient. This number was increased by 20% in case there were patients who wanted to leave the study. Patients were assigned to the control (n=32) and intervention groups (n=32) by simple randomisation.
The inclusion criteria were patients aged 18 years and over, diagnosed with breast cancer, receiving active hormone therapy, experiencing hot flush symptoms and volunteering to participate in the study. Patients who were in menopause and had verbal and auditory communication problems were excluded from the study.
Randomisation A total of 90 patients who met the inclusion criteria were reached. Since 10 of the 90 patients did not meet the inclusion criteria, 80 patients were assigned to the groups by simple randomisation (40 in the intervention group and 40 in the control group). In order to minimise selection bias, a table of random numbers from the simple random sampling method, which is one of the probability sampling methods, was used. Since 5 of the 40 patients randomly assigned to the intervention group refused to participate in the study and 3 of them continued to receive treatment in another hospital, the study was terminated with 32 patients. Of the 40 patients randomly assigned to the control group, the study was terminated with a total of 32 patients because 6 refused to participate in the study and 2 left due to interruption of treatment.
Measurements Research data were collected using the "Individual Information Form", "Visual Analog Scale (VAS)" and "Hot Flash Belief Scale" prepared by the researchers in line with the literature. Individual Information Form; the form prepared by the researchers consisted of 13 questions regarding the individuals' age, gender, place of residence, number of children, marital status, educational status, employment status, economic status, chronic disease status, duration of cancer diagnosis, cancer stage, treatments received, and practices performed to prevent symptoms15.
Visual Analog Scale (VAS); VAS is used to quantify some values that cannot be measured numerically. It consists of a 10 cm long line at one end, which is expressed as very good for the individual/patient and very bad at the other end. VAS is also a valid and reliable measurement tool for measuring other subjective emotions such as mood. In this study, VAS is preferred for the hot flashes experienced by women with breast cancer receiving hormone therapy.
Hot Flashes Belief Scale; The scale consists of 27 items and three sub-dimensions. The beliefs about oneself in a social context sub-dimension: It was formed with 13 items (1, 6-11, 13,14, 17, 20, 21, 23) that describe how women feel when they experience hot flashes in social environments. The beliefs about coping with hot flashes sub-dimension: It was formed with 10 items (2, 5, 12, 15, 16, 18, 19, 24, 26, 27) that describe beliefs about coping with hot flashes. Beliefs about coping with night sweats sub-dimension: It consists of 4 items (3, 4, 22, 25) describing women's beliefs about coping with night sweats. Each item of the scale is rated on a 6- point Likert type scale ranging from "strongly disagree" (0 points) to "strongly agree" (5 points). It is stated that items 2, 4, 5, 11, 15, 18, 25 of the scale are reverse coded. The total score of the scale varies between 0-135, and a high score on the scale indicates a high level of negative belief. The reliability analysis conducted for the Hot Flash Belief Scale and its sub-dimensions shows that there is a high internal consistency in the scale. The total Cronbach's Alpha value of the scale was calculated as 0.950, and 0.941 for social belief, 0.933 for coping, and 0.946 for night sweats were found for the sub-dimensions. All Alpha values above 0.90 indicate that the scale is a reliable measurement tool in general and at the sub-dimensions.
Data Collection The data of the study were collected by the researcher using face-to-face interview method in the outpatient chemotherapy unit between November 2023 and October 2024. The data collection process took approximately 15-20 minutes. After the patients who met the inclusion criteria were informed about the purpose of the study, the application and the data collection process, their verbal and written consents were obtained. The experimental group (hand fan) who accepted the study were administered the pre-test (Hot flush VAS-Hot Flush Belief Scale) on the first day they came to the outpatient clinic and the post- test (Hot flush VAS-Hot Flush Belief Scale) when they came to the second control (at least 3 months).
Patients in the experimental group were given a hand fan and asked to use the hand fan when they felt hot flushes. They were also reminded to use the hand fan by calling twice a week.
The control group who accepted the study will be administered the pre-test (Hot flush VAS-Hot Flush Belief Scale) on the first day of their visit to the outpatient clinic and the post-test (Hot flush VAS-Hot Flush Belief Scale) on the second visit (at least 3 months).
Data Analysis Data were analyzed using Statistical Social Sciences Package 26.0. Descriptive statistics including mean, standard deviation, frequency, minimum and maximum values were used to evaluate the data. Homogeneity of the study groups was tested using Pearson chi-square analysis and independent samples t-tests. Comparisons of two independent groups were performed using Mann-Whitney U tests and p<.05 was considered statistically significant. Post-hoc power analysis was performed using G*Power software to evaluate the statistical power of ANOVA test in this study. For the analysis, the effect size (f) was determined as 0.25, α error probability was 0.05 and a total sample size of 386 was considered; four groups were considered. The results show that the noncentrality parameter was 24.13, the critical F value was 2.63 and the power (1 - β error probability) value was 99%. These findings reveal that the study has high statistical power and increase the reliability of the results.
Ethical Consideration Prior to the study, approval was obtained from the Izmir Bakırçay University Non-Interventional Clinical Research Ethics Committee (decision no/date: 1266/01.11.2023). The Declaration ofHelsinki was followed at all stages of the study. Informed consent was obtained from all participants and they were given a commitment to withdraw from the study at any time.
- Conditions
- Breast Cancer, Handheld Fan, Hot Flashes, Hormonetherapy
- Being tested
- Handheld fan, Control Group
- Keywords
- breast cancer, hormonetherapy, handheld fan, hot flashes, symptom management
- Medical subject headings
- Breast Neoplasms, Hot Flashes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Handheld fanOther
Group using hand fans
Control GroupOther
pre-test, mid-test and post-test will be administered.
| Study group | Role | What they receive |
|---|---|---|
| Control group | No intervention | pre-test, mid-test and final test will be administered. |
| İntervention group | Experimental | Group using hand fans Receives: Other: Handheld fan; Other: Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Individual Information Form
This form contains questions about sociodemographic characteristics, diseases and symptoms.
Measured: 12 weeks
Visual Analog Scale (VAS)
Visual Analog Scale (VAS); VAS is used to quantify some values that cannot be measured numerically. It consists of a 10 cm long line at one end, which is expressed as very good for the individual/patient and very bad at the other end. VAS is also a valid and reliable measurement tool for measuring other subjective emotions such as mood. In this study, VAS is preferred for the hot flashes experienced by women with breast cancer receiving hormone therapy
Measured: 12 weeks
Hot Flashes Belief Scale
The scale consists of 27 items and three sub-dimensions. The beliefs about oneself in a social context sub-dimension: It was formed with 13 items (1, 6-11, 13, 14, 17, 20, 21, 23) that describe how women feel when they experience hot flashes in social environments. The beliefs about coping with hot flashes sub-dimension: It was formed with 10 items (2, 5, 12, 15, 16, 18, 19, 24, 26, 27) that describe beliefs about coping with hot flashes. Beliefs about coping with night sweats sub-dimension: It consists of 4 items (3, 4, 22, 25) describing women's beliefs about coping with night sweats. Each item of the scale is rated on a 6-point Likert type scale ranging from "strongly disagree" (0 points) to "strongly agree" (5 points). It is stated that items 2, 4, 5, 11, 15, 18, 25 of the scale are reverse coded. The total score of the scale varies between 0-135, and a high score on the scale indicates a high level of negative belief.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2025
- Study start15 Nov 2023
- Primary completion15 Jan 2024
- Study completion15 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- This study was conducted in a single-blind, single-center, randomized controlled design in breast cancer patients receiving hormone therapy in an outpatient chemotherapy unit. This study was conducted in the outpatient chemotherapy unit of a training and research university hospital in Turkey between November 2023 and October 2024.: This randomised controlled study was a pretest-posttest experimental design. The study sample consisted of 64 breast cancer patients (n = 32 for each of the intervention and control groups) receiving hormone therapy treatment in the medical oncology department of a university hospital. The intervention group used a hand-held fan when experiencing hot flush symptoms, while the control group did not receive any intervention.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Izmir Bakircay University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aslıhan ÖZTÜRK ÇETİN, Izmir Bakircay University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07054957
- Sponsor's protocol ID
- Bakırçay Üniversitesi
- Acronym
- Breast Cancer
- Status last verified
- Jul 2025
- First submitted
- 3 Jun 2025
- Last updated
- 8 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of Handheld Fans in Management of Hot Flashes in Women With Breast Cancer Receiving Hormonetherapy
- ClinicalTrials.gov ID
- NCT07054957
- Acronym / sponsor ID
- Breast Cancer / Bakırçay Üniversitesi
- Conditions
- Breast Cancer, Handheld Fan, Hot Flashes, Hormonetherapy
- Keywords
- breast cancer, hormonetherapy, handheld fan, hot flashes, symptom management
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Izmir Bakircay UniversityUniversity, hospital or other
- Study start
- 15 Nov 2023 (actual)
- Primary completion
- 15 Jan 2024 (actual)
- Study completion
- 15 Oct 2024 (actual)
- First posted
- 8 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hot flushes are a common symptom in women with breast cancer receiving hormone therapy. It can lead to conditions that reduce quality of life such as sleep quality deterioration, sexual problems and discomfort in daily life. Effective management of the symptom improves the quality of life of patients.
The aim of the study was to examine the effect of handheld fan use in the management of hot flashes in women with breast cancer receiving hormone therapy.
Hypotheses of the research:
H1: Handheld fan use has no effect in managing hot flashes in women with breast cancer receiving hormone therapy. H2: The use of handheld fan has an effect on the management of hot flashes in women with breast cancer receiving hormone therapy. This randomised controlled study was a pretest-posttest experimental design. The study sample consisted of 64 breast cancer patients (n = 32 for each of the intervention and control groups) receiving hormone therapy treatment in the medical oncology department of a university hospital. The intervention group used a hand-held fan when experiencing hot flush symptoms, while the control group did not receive any intervention. The pre-test and post-test Visual Analogue Scale (VAS) and hot flush belief scale scores and the results of the individual identifying information form were compared for both groups.
Detailed description
Study Design This study was conducted in a single-blind, single-center, randomized controlled design in breast cancer patients receiving hormone therapy in an outpatient chemotherapy unit.
This study was conducted in the outpatient chemotherapy unit of a training and research university hospital in Turkey Participants Power analysis was performed to determine the sample size of the study and the power of the test was calculated with G*Power 3.1 programme. Accordingly, with a margin of error of α=.05 and 80% power level, a total of 52 people, 26 people in each group, were found sufficient. This number was increased by 20% in case there were patients who wanted to leave the study. Patients were assigned to the control (n=32) and intervention groups (n=32) by simple randomisation.
The inclusion criteria were patients aged 18 years and over, diagnosed with breast cancer, receiving active hormone therapy, experiencing hot flush symptoms and volunteering to participate in the study. Patients who were in menopause and had verbal and auditory communication problems were excluded from the study.
Randomisation A total of 90 patients who met the inclusion criteria were reached. Since 10 of the 90 patients did not meet the inclusion criteria, 80 patients were assigned to the groups by simple randomisation (40 in the intervention group and 40 in the control group). In order to minimise selection bias, a table of random numbers from the simple random sampling method, which is one of the probability sampling methods, was used. Since 5 of the 40 patients randomly assigned to the intervention group refused to participate in the study and 3 of them continued to receive treatment in another hospital, the study was terminated with 32 patients. Of the 40 patients randomly assigned to the control group, the study was terminated with a total of 32 patients because 6 refused to participate in the study and 2 left due to interruption of treatment.
Measurements Research data were collected using the "Individual Information Form", "Visual Analog Scale (VAS)" and "Hot Flash Belief Scale" prepared by the researchers in line with the literature. Individual Information Form; the form prepared by the researchers consisted of 13 questions regarding the individuals' age, gender, place of residence, number of children, marital status, educational status, employment status, economic status, chronic disease status, duration of cancer diagnosis, cancer stage, treatments received, and practices performed to prevent symptoms15.
Visual Analog Scale (VAS); VAS is used to quantify some values that cannot be measured numerically. It consists of a 10 cm long line at one end, which is expressed as very good for the individual/patient and very bad at the other end. VAS is also a valid and reliable measurement tool for measuring other subjective emotions such as mood. In this study, VAS is preferred for the hot flashes experienced by women with breast cancer receiving hormone therapy.
Hot Flashes Belief Scale; The scale consists of 27 items and three sub-dimensions. The beliefs about oneself in a social context sub-dimension: It was formed with 13 items (1, 6-11, 13,14, 17, 20, 21, 23) that describe how women feel when they experience hot flashes in social environments. The beliefs about coping with hot flashes sub-dimension: It was formed with 10 items (2, 5, 12, 15, 16, 18, 19, 24, 26, 27) that describe beliefs about coping with hot flashes. Beliefs about coping with night sweats sub-dimension: It consists of 4 items (3, 4, 22, 25) describing women's beliefs about coping with night sweats. Each item of the scale is rated on a 6- point Likert type scale ranging from "strongly disagree" (0 points) to "strongly agree" (5 points). It is stated that items 2, 4, 5, 11, 15, 18, 25 of the scale are reverse coded. The total score of the scale varies between 0-135, and a high score on the scale indicates a high level of negative belief. The reliability analysis conducted for the Hot Flash Belief Scale and its sub-dimensions shows that there is a high internal consistency in the scale. The total Cronbach's Alpha value of the scale was calculated as 0.950, and 0.941 for social belief, 0.933 for coping, and 0.946 for night sweats were found for the sub-dimensions. All Alpha values above 0.90 indicate that the scale is a reliable measurement tool in general and at the sub-dimensions.
Data Collection The data of the study were collected by the researcher using face-to-face interview method in the outpatient chemotherapy unit between November 2023 and October 2024. The data collection process took approximately 15-20 minutes. After the patients who met the inclusion criteria were informed about the purpose of the study, the application and the data collection process, their verbal and written consents were obtained. The experimental group (hand fan) who accepted the study were administered the pre-test (Hot flush VAS-Hot Flush Belief Scale) on the first day they came to the outpatient clinic and the post- test (Hot flush VAS-Hot Flush Belief Scale) when they came to the second control (at least 3 months).
Patients in the experimental group were given a hand fan and asked to use the hand fan when they felt hot flushes. They were also reminded to use the hand fan by calling twice a week.
The control group who accepted the study will be administered the pre-test (Hot flush VAS-Hot Flush Belief Scale) on the first day of their visit to the outpatient clinic and the post-test (Hot flush VAS-Hot Flush Belief Scale) on the second visit (at least 3 months).
Data Analysis Data were analyzed using Statistical Social Sciences Package 26.0. Descriptive statistics including mean, standard deviation, frequency, minimum and maximum values were used to evaluate the data. Homogeneity of the study groups was tested using Pearson chi-square analysis and independent samples t-tests. Comparisons of two independent groups were performed using Mann-Whitney U tests and p<.05 was considered statistically significant. Post-hoc power analysis was performed using G*Power software to evaluate the statistical power of ANOVA test in this study. For the analysis, the effect size (f) was determined as 0.25, α error probability was 0.05 and a total sample size of 386 was considered; four groups were considered. The results show that the noncentrality parameter was 24.13, the critical F value was 2.63 and the power (1 - β error probability) value was 99%. These findings reveal that the study has high statistical power and increase the reliability of the results.
Ethical Consideration Prior to the study, approval was obtained from the Izmir Bakırçay University Non-Interventional Clinical Research Ethics Committee (decision no/date: 1266/01.11.2023). The Declaration ofHelsinki was followed at all stages of the study. Informed consent was obtained from all participants and they were given a commitment to withdraw from the study at any time.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This study was conducted in a single-blind, single-center, randomized controlled design in breast cancer patients receiving hormone therapy in an outpatient chemotherapy unit. This study was conducted in the outpatient chemotherapy unit of a training and research university hospital in Turkey between November 2023 and October 2024.: This randomised controlled study was a pretest-posttest experimental design. The study sample consisted of 64 breast cancer patients (n = 32 for each of the intervention and control groups) receiving hormone therapy treatment in the medical oncology department of a university hospital. The intervention group used a hand-held fan when experiencing hot flush symptoms, while the control group did not receive any intervention.
| Arm | Type | Receives |
|---|---|---|
| Control group | No intervention | –pre-test, mid-test and final test will be administered. |
| İntervention group | Experimental | Other: Handheld fan, Other: Control GroupGroup using hand fans |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Diagnosis of clinical breast cancer
- Experiencing hot flashes
Key exclusion criteria (1 listed)
- Menopausal women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Handheld fanGroup using hand fans | Other | İntervention group |
| Control Grouppre-test, mid-test and post-test will be administered. | Other | İntervention group |
Primary outcome
Individual Information Form
Time frame: 12 weeks
This form contains questions about sociodemographic characteristics, diseases and symptoms.
Visual Analog Scale (VAS)
Time frame: 12 weeks
Visual Analog Scale (VAS); VAS is used to quantify some values that cannot be measured numerically. It consists of a 10 cm long line at one end, which is expressed as very good for the individual/patient and very bad at the other end. VAS is also a valid and reliable measurement tool for measuring other subjective emotions such as mood. In this study, VAS is preferred for the hot flashes experienced by women with breast cancer receiving hormone therapy
Hot Flashes Belief Scale
Time frame: 12 weeks
The scale consists of 27 items and three sub-dimensions. The beliefs about oneself in a social context sub-dimension: It was formed with 13 items (1, 6-11, 13, 14, 17, 20, 21, 23) that describe how women feel when they experience hot flashes in social environments. The beliefs about coping with hot flashes sub-dimension: It was formed with 10 items (2, 5, 12, 15, 16, 18, 19, 24, 26, 27) that describe beliefs about coping with hot flashes. Beliefs about coping with night sweats sub-dimension: It consists of 4 items (3, 4, 22, 25) describing women's beliefs about coping with night sweats. Each item of the scale is rated on a 6-point Likert type scale ranging from "strongly disagree" (0 points) to "strongly agree" (5 points). It is stated that items 2, 4, 5, 11, 15, 18, 25 of the scale are reverse coded. The total score of the scale varies between 0-135, and a high score on the scale indicates a high level of negative belief.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Handheld fan in people with Breast Cancer and Handheld Fan, run by Izmir Bakircay University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Individual Information Form (time frame: 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2025.